Alnylam Pharmaceuticals Inc $ 172.38 5.63 (3.38%)
Volume:
534,530
Avg Vol (1m):
650,188
Market Cap $:
20.03 Bil
Enterprise Value $:
18.52 Bil
P/E (TTM):
0.00
P/B:
16.45
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 5.57 | ||
| Equity-to-Asset | 0.37 | ||
| Debt-to-Equity | 0.27 | ||
| Debt-to-EBITDA | -0.39 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 3.77 | ||
| Beneish M-Score | 4.92 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -232.51 | ||
| Net Margin % | -222.19 | ||
| ROE % | -63.54 | ||
| ROA % | -32.05 | ||
| ROC (Joel Greenblatt) % | -139.69 | ||
| 3-Year Revenue Growth Rate | 54 | ||
| 3-Year EBITDA Growth Rate | -19.2 | ||
| 3-Year EPS without NRI Growth Rate | -19.2 |
ALNY
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 16.45 | ||
| PS Ratio | 49.07 | ||
| EV-to-EBIT | -20.24 | ||
| EV-to-EBITDA | -21.87 | ||
| EV-to-Revenue | 46.19 | ||
| Current Ratio | 4.28 | ||
| Quick Ratio | 4.14 | ||
| Days Inventory | 351.48 | ||
| Days Sales Outstanding | 72.02 | ||
| Days Payable | 151.38 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 16.45 | ||
| Price-to-Median-PS-Value | 0.56 | ||
| Earnings Yield (Greenblatt) % | -4.94 |